Bone cancer or osteosarcoma is a highly aggressive cancer that frequently affects both dogs and children. Treatment currently consists of limb amputation or limb-sparing surgery and chemotherapy. Unfortunately, even with aggressive treatment, once this cancer spreads (metastasizes) to the lungs, it becomes incredibly difficult to treat. The majority of dogs and children die from the spread of cancer to their lungs. During the process of tumor growth, cancer cells break off, enter the blood, and circulate through the body; these cells eventually cause metastasis. However, little is known about the processes that affect where these cells go, and what changes occur in them that allows them to spread to the lungs. This trial will evaluate circulating tumor cells in dogs with osteosarcoma and determine how their activity changes throughout the course of surgery, chemotherapy, and during follow-up. Information gained from this study will help us modify existing treatments and develop new therapies that disrupt the pathways that lead to the spread of osteosarcoma in dogs and children.
What qualifies my pet for this trial?
To participate in this clinical trial your dog must be newly diagnosed with osteosarcoma
What does enrolling in this clinical trial involve?
Dogs enrolled in this study will undergo standard of care treatments for osteosarcoma. This includes amputation of the affected limb, followed by 4 doses of intravenous carboplatin chemotherapy given on an every 21 day schedule. Whole blood will be collected from your dog at the designated study visits to isolate circulating tumor cells as well as measure serum IL-6 levels. In most cases, blood collections associated with this clinical trial will coincide with every cycle of chemotherapy (every 3 weeks) and whole blood will be collected at the same time that your dog is undergoing a routine blood draw for planned chemotherapy administration. After your dog has completed chemotherapy treatments, there will be designated study visits when your dog will experience a separate blood collection (because no blood draw or chemotherapy administration is planned at the clinical visit). These additional blood collections will occur at routine re-staging visits (every 3 months after completion of chemotherapy) and at the time that your dog develops metastasis, if it develops metastasis. In the event that you chose to euthanize your dog, you will be asked to participate in a separate study at that time in order to collect a small piece of tumor tissue after euthanasia is performed.
This study will cover the cost of CBCs that occur as a part of treatment. Further details may be found in the informed consent form.
Dr. Camille McAloney